Valsartan
- TRADE NAMES: Byvalson (Forest); Diovan (Novartis); Diovan HCT (Novartis); Exforge (Novartis); Valturna (Novartis)
- INDICATIONS: Hypertension
- CLASS: Angiotensin receptor antagonist (blocker), Antihypertensive
- HALF-LIFE: 9 hours
None known
PREGNANCY CATEGORY: D
Byvalson is valsartan and nebivolol; Exforge is valsartan and amlodipine; Valturna is valsartan and aliskiren; Diovan HCT is valsartan and hydrochlorothiazide.
Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
See also separate profile for Sacubitril/Valsartan.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of valsartan in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric